236 related articles for article (PubMed ID: 37568798)
1. Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities-A Systematic Review.
Klekowski J; Zielińska D; Hofman A; Zajdel N; Gajdzis P; Chabowski M
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568798
[TBL] [Abstract][Full Text] [Related]
2. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
Oncology; 2024; 102(6):503-509. PubMed ID: 38043528
[TBL] [Abstract][Full Text] [Related]
3. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
4. High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.
Wang X; Xing Z; Chen H; Yang H; Wang Q; Xing T
Front Oncol; 2022; 12():953529. PubMed ID: 36059705
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
6. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
[TBL] [Abstract][Full Text] [Related]
7. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
[TBL] [Abstract][Full Text] [Related]
8. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
[TBL] [Abstract][Full Text] [Related]
9. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
[TBL] [Abstract][Full Text] [Related]
10. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
11. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Potential of Nectin Expressions in Colorectal Cancer: An Exploratory Study.
Kobecki J; Gajdzis P; Mazur G; Chabowski M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958883
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic prospects of nectin-4 in cancer: applications and value.
Li K; Zhou Y; Zang M; Jin X; Li X
Front Oncol; 2024; 14():1354543. PubMed ID: 38606099
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Wong RL; Yu EY
Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
[TBL] [Abstract][Full Text] [Related]
15. Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression.
Miyake M; Miyamoto T; Shimizu T; Ohnishi S; Fujii T; Nishimura N; Oda Y; Morizawa Y; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
Pathol Res Pract; 2022 Sep; 237():154072. PubMed ID: 35986963
[TBL] [Abstract][Full Text] [Related]
16. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
[No Abstract] [Full Text] [Related]
17. Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy.
Chatterjee S; Sinha S; Kundu CN
Eur J Pharmacol; 2021 Nov; 911():174516. PubMed ID: 34547246
[TBL] [Abstract][Full Text] [Related]
18. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Filippi L; Schillaci O
Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
[TBL] [Abstract][Full Text] [Related]
20. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
Bouleftour W; Guillot A; Magne N
Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
